Directorio de personas
Luis Brieva Ruiz

Luis Brieva Ruiz

Grado: Doctor/a

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3812-2011

Publicaciones

  • Quirant-Sanchez, B; Presas-Rodriguez, S; Mansilla, MJ; Teniente-Serra, A; Hervas-Garcia, JV; Brieva, L; Moral-Torres, E; Cano, A; Munteis, E; Navarro-Barriuso, J; Martinez-Caceres, EM; Ramo-Tello, C

    Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

    Mediators of Inflammation 2019 8147803-8147803. .

    [doi:10.1155/2019/8147803]

  • Sepulveda, M; Aldea, M; Escudero, D; Llufriu, S; Arrambide, G; Otero-Romero, S; Sastre-Garriga, J; Romero-Pinel, L; Martinez-Yelamos, S; Sola-Valls, N; Armangue, T; Sotoca, J; Escartin, A; Robles-Cedeno, R; Ramio-Torrent, L; Presas-Rodriguez, S; Ramo-Tello, C; Munteis, E; Pelayo, R; Gubieras, L; Brieva, L; Ortiz, N; Hervas, M; Mañé-Martínez MA; Cano, A; Vela, E; Tintore, M; Blanco, Y; Montalban, X; Graus, F; Saiz, A

    Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    MULTIPLE SCLEROSIS JOURNAL 24 1843-1851. .

    [doi:10.1177/1352458517735191]

  • Quirant-Sanchez, B; Hervas-Garcia, JV; Teniente-Serra, A; Brieva, L; Moral-Torres, E; Cano, A; Munteis, E; Mansilla, MJ; Presas-Rodriguez, S; Navarro-Barriuso, J; Ramo-Tello, C; Martinez-Caceres, EM

    Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    Cns Neuroscience & Therapeutics 24 1175-1184. .

    [doi:10.1111/cns.12851]

  • Gil, A; Pardinas, B; Hervas, V; Lecina, J; Solana, MJ; Peralta, S; Forne, C; Gonzalez, C; Gonzalo, H; Nogueras, L; Brieva, L

    Pilot Study of Telemedicine in multiple sclerosis to evaluate the effectiveness of a telecommunication system for the detection of the clinical activity of the disease in the number of relapses with respect to the standard clinical practice. TELEM

    MULTIPLE SCLEROSIS JOURNAL 24 795-796. .

  • Fernandez, O; Tintore, M; Saiz, A; Calles-Hernandez, MC; Comabella, M; Ramio-Torrenta, L; Oterino, A; Izquierdo, G; Tellez, N; Garcia-Merino, JA; Brieva, L; Arnal-Garcia, C; Aladro, Y; Mendibe-Bilbao, MD; Meca-Lallana, JE; Romero-Pinel, L; Ginestal, R; Martinez-Gines, ML; Arroyo, R; Rodriguez-Antiguedad, A

    Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post- ECTRIMS Meeting ( II)

    REVISTA DE NEUROLOGIA 67 50-62. .

    [doi:10.33588/rn.6702.2018193]

  • Fernandez, O; Tintore, M; Saiz, A; Calles-Hernandez, MC; Comabella, M; Ramio-Torrenta, L; Oterino, A; Izquierdo, G; Tellez, N; Garcia-Merino, JA; Brieva, L; Arnal-Garcia, C; Aladro, Y; Mendibe-Bilbao, MD; Meca-Lallana, JE; Romero-Pinel, L; Ginestal, R; Martinez-Gines, ML; Arroyo, R; Rodriguez-Antiguedad, A

    Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I)

    REVISTA DE NEUROLOGIA 67 15-27. .

    [doi:10.33588/rn.6701.2018192]

  • Ramo-Tello, C.; Hervas-Garcia, J-V; Presas-Rodriguez, S.; Capallades, J.; Ramio-Torrenta, L.; Brieva, L.; Batlle, J.; Moral, E.; Blanco, Y.; Cano, A.; Torres, F.

    A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: the Oral-CORTEM trial

    MULTIPLE SCLEROSIS JOURNAL 23 403-403. .

  • Sepulveda, M.; Aldea, M.; Escudero, D.; Llufriu, S.; Arrambide, G.; Otero-Romero, S.; Sastre-Garriga, J.; Romero-Pinel, L.; Martinez-Yelamos, S.; Sola-Valls, N.; Armangue, T.; Sotoca, J.; Escartin, A.; Robles, R.; Ramio-Torrenta, L.; Presas, S.; Ramo, C.; Munteis, E.; Pelayo, R.; Gubieras, L.; Brieva, L.; Ortiz, N.; Hervas, M.; Mane-Martinez, M. A.; Cano, A.; Vela, E.; Tintore, M.; Blanco, Y.; Montalban, X.; Graus, F.; Saiz, A.

    Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-based study

    MULTIPLE SCLEROSIS JOURNAL 23 91-92. .

  • Nogueras Penabad, L.; Gil Sanchez, A.; Hervas, J. V.; Gonzalez, C.; Marti, M.; Canudes, M.; Peralta, S.; Moga, M. J.; Boada, J.; Pamplona, R.; Portero, M.; Brieva, L.; Gonzalo, H.

    Mitochondrial dysfunction in peripheral blood mononuclear cells from multiple sclerosis patients

    MULTIPLE SCLEROSIS JOURNAL 23 509-509. .

  • Gonzalez-Mingot, C; Sanchez-Monge, IR; Purroy, F; Solana-Moga, MJ; Peralta-Moncusi, S; Lazo-Latorre, C; Gil-Villar, MP; Brieva, L

    Environmental-analytical risk factors influence on the phenotype of amyotrophic lateral sclerosis in a rural setting

    REVISTA DE NEUROLOGIA 65 203-208. .

    [doi:10.33588/rn.6505.2017091]

  • Fernandez, O; Oterino, A; Oreja-Guevara, C; Prieto, JM; del Mar Mendibe-Bilbao, Maria; Garcia-Merino, JA; Ramio-Torrenta, L; Ginestal, R; Meca-Lallana, JE; Romero-Pinel, L; Munoz, D; Oliva-Nacarino, P; Carmen Calles-Hernandez, M.; Izquierdo, G; Luisa Martinez-Gines, M.; Saiz, A; Comabella, M; Casanova-Estruch, B; Brieva, L; Arroyo, R; Rodriguez-Antiguedad, A

    Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II)

    REVISTA DE NEUROLOGIA 65 75-84. .

    [doi:10.33588/rn.6502.2017169]

  • Fernandez, O; Oterino, A; Oreja-Guevara, C; Prieto, JM; del Mar Mendibe-Bilbao, Mara; Garcia-Merino, JA; Ramio-Torrenta, L; Ginestal, R; Meca-Lallana, JE; Romero-Pinel, L; Munoz, D; Oliva-Nacarino, P; Carmen Calles-Hernandez, M.; Izquierdo, G; Luisa Martinez-Gines, M.; Saiz, A; Comabella, M; Casanova-Estruch, B; Brieva, L; Arroyo, R; Rodriguez-Antiguedad, A

    Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I)

    REVISTA DE NEUROLOGIA 65 31-40. .

    [doi:10.33588/rn.6501.2017168]

Proyectos

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"
  • UTILIDAD DE LA REALIZACION DE SECUENCIAS DE DIFUSION Y LA DETERMINACION DE BIOMARCADORES EN EL PRONOSTICO DE LOS PACIENTES CON UN ATAQUE ISQUEMICO TRANSITORIO